14th Conference on Retroviruses and Opportunistic Infections (CROI 2007)

Author:

Hirschel Bernard1

Affiliation:

1. Geneva University Hospital, Rue Micheli du Crest 24,1205 Geneva, Switzerland.

Publisher

Future Medicine Ltd

Subject

Pharmacology (medical),Infectious Diseases,Virology,Drug Discovery,Pharmacology

Reference14 articles.

1. CooperD, Gatell J, Rockstroh Jet al.: Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus.Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007 (Abstract 105aLB).

2. SteigbigelR, Kumar P, Eron Jet al.: Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus.Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007 (Abstract 105bLB).

3. NelsonM, Fätkenheuer G, Konourina Iet al.: Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results.Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007 (Abstract 104aLB).

4. LalezariJ, Goodrich J, DeJesus Eet al.: Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a Phase 2b/3 study in the US and Canada.Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007 (Abstract 104bLB).

5. PozniakA, Morales-Ramirez J, Mohapi Let al.: 48-week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naive patients.Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007 (Abstract 144LB).

Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. References;Breastfeeding;2022

2. Caspase-1 Activation Is Related With HIV-Associated Atherosclerosis in an HIV Transgenic Mouse Model and HIV Patient Cohort;Arteriosclerosis, Thrombosis, and Vascular Biology;2019-09

3. Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing;CPT: Pharmacometrics & Systems Pharmacology;2019-07-10

4. HIV-1–Associated Atherosclerosis;Journal of the American College of Cardiology;2017-06

5. The Antiviral Immune Response and Its Impact on the HIV-1 Reservoir;Current Topics in Microbiology and Immunology;2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3